Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Washington University Dantrolene Study in Wolfram Syndrome

Also known as: Dantrolene, dantrolene sodium, A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome, NCT02829268

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 1/2

Status

Completed

Target Gene

—

Route / Mode

Oral

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

genetic, syndromic, pediatric, adult

Trial IDs

Mechanism

Completed Phase 1b/2a institution-led trial evaluating oral dantrolene sodium safety, tolerability, and effects on cardinal manifestations of Wolfram syndrome, a syndromic condition with hearing-loss relevance.

Indications

Hearing Loss Sensorineural Hearing Loss

Notes

Verified as a completed academic dantrolene sodium study in Wolfram syndrome. HearScape includes it as hearing-adjacent through syndromic disease context rather than as a dedicated hearing-loss drug program.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT02829268

Open

Key Events

2017-01-01

Registry lists actual start of dantrolene sodium Wolfram syndrome trial

2023-02-01

Registry lists actual completion of dantrolene sodium Wolfram syndrome trial

Clinical Trials (1)